Researchers identified somatic KRAS mutations in affected tissue from more than 60 percent of people with sporadic arteriovenous malformations of the brain.
The team has developed a method to test for inherited disorders prenatally and plan to conduct a larger trial and eventually offer it as a clinical test.
The firm has not published validation studies for the test, but new data last week has provided more support for the methylation-based method at its heart.
The Associated Press reports that an ethicist predicts that prenatal diagnosis and other advances will lead to more choices being available to prospective parents.
